Overview

Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies

Status:
Terminated
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This is a phase II study to assess the day 180 event free and overall survival after administration of a specified combination of fludarabine, busulfan, Total Body Irradiation (TBI), and thymoglobulin reduced intensity conditioning and 2 unit UCB stem cell transplant in a single institution setting in patients with hematologic malignancies for whom allogeneic transplantation is indicated.
Phase:
Phase 2
Details
Lead Sponsor:
University of Virginia
Treatments:
Busulfan
Fludarabine
Thymoglobulin